156 related articles for article (PubMed ID: 9200452)
1. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
3. Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action.
Xu X; Gong H; Blinder L; Shen J; Williams JW; Chong AS
J Pharmacol Exp Ther; 1997 Nov; 283(2):869-75. PubMed ID: 9353408
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
5. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
6. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
7. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
8. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
10. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
Fukushima R; Kanamori S; Hirashiba M; Hishikawa A; Muranaka R; Kaneto M; Kitagawa H
Toxicol Sci; 2009 Apr; 108(2):419-26. PubMed ID: 19190124
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
[TBL] [Abstract][Full Text] [Related]
16. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726.
Seah QM; New LS; Chan EC; Boelsterli UA
Drug Metab Lett; 2008 Aug; 2(3):153-7. PubMed ID: 19356086
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.
Elder RT; Xu X; Williams JW; Gong H; Finnegan A; Chong AS
J Immunol; 1997 Jul; 159(1):22-7. PubMed ID: 9200434
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Moss D; Thomson TA; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
J Biol Chem; 1995 Sep; 270(38):22467-72. PubMed ID: 7673235
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
